Maxwell Biosciences

Discover how Maxwell Biosciences is advancing biodefense with its Claromer™ platform in an exclusive Contract Pharma interview. CEO Joshua McClure discusses U.S. Military partnerships, a $3M MTEC award and innovative therapeutics for infectious diseases like Dengue Fever. Read the full story to explore Maxwell's vision for global health security: https://lnkd.in/egAyNsDE

ICYMI: Maxwell Biosciences CEO on Claromers™ and the Future of Longevity In a recent Lifespan.io Longevity News interview, Maxwell CEO Joshua McClure dives into how Claromers™—synthetic small molecules mimicking the immune peptide LL-37—could transform healthspan by combating infectious disease. From nonhuman primate trials to collaborations with the US military and India, McClure outlines a bold vision: eradicating infections as the primary driver of aging. Read the full interview here: https://lnkd.in/e8GJr-yA

Maxwell Biosciences announces that Edward M. Rudnic, Ph.D., our COO and Head of R&D, will speak at the 12th Annual Aging Research & Drug Discovery Meeting (ARDD 2025), the preeminent conference in aging research and longevity. Hosted by the University of Copenhagen, ARDD 2025 runs August 25-29 at the Ceremonial Hall and will also be streaming online. The 2025 program brings together global authorities in longevity, including Nobel laureates Morten Meldal and Michael Levitt, to address advancements in aging science and drug discovery. Join us—tickets are available for virtual or in-person attendance. Register at agingpharma.org. #ARDD2025 #AgingResearch #Longevity

Maxwell Biosciences is pleased to sponsor the 12th Aging Research & Drug Discovery Meeting (#ARDD2025), the preeminent event in aging research and longevity technology. This year’s meeting runs August 25-29, 2025 at the University of Copenhagen's Ceremonial Hall. The event will also stream online. According the United Nations, people over 65 now outnumber children under 5—a shift driving new challenges and opportunities in age-related disease research. At #ARDD2025, global thought-leaders, including Nobel laureates Morten Meldal and Michael Levitt, will share groundbreaking insights on targeting the aging process to improve healthspan. This is the world’s largest conference of its kind, bringing together academic luminaries, biotech innovators, and pharma leaders from companies like Novartis and Eli Lilly. We hope you’ll join us—virtual and in-person tickets are available. Register now at agingpharma.org. #ARDD2025 #AgingResearch #Longevity

📢 Maxwell Biosciences Secures US Army Agreement to Research Core Scientific Aspects of Claromer™ Technology Maxwell Biosciences is proud to announce a new Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research (USAISR). Together, we’re learning more about the core scientific aspects of our Claromer™ technology—synthetic molecules inspired by the immune system. This collaboration—our sixth with U.S. military branches—fuels our mission to create next-generation therapeutics. Insights gained here will shape the future of our “One Drug for Many Bugs” approach. “The Claromer™ family of compounds represents a novel breakthrough, “ said Joshua McClure, CEO of Maxwell Biosciences. “We’re delighted that the U.S. Army is as equally motivated as we are to research fundamental scientific aspects of these compounds. There’s so much we can learn by working hand-in-hand with military scientists.” Read more here. 👉 https://lnkd.in/edAA3wHU

📢 Maxwell Biosciences Partners with U.S. Military to Fight Dengue Dengue cases are surging—12M infections hit the Americas in 2024 alone. Maxwell Biosciences is taking action. We’re proud to announce a new collaboration with the Naval Medical Research Command to develop antiviral therapeutics for dengue virus, the world’s fastest-growing mosquito-borne disease. Through this partnership, the Naval Medical Infectious Diseases Diagnostic Laboratory will test our Claromer™ compounds against all four strains of dengue fever. Dengue cases have doubled every year since 2021. With no effective antiviral treatment, the need for innovative, shelf-stable solutions has never been greater. "At Maxwell, we’re honored to partner with the U.S. military to tackle the most difficult diseases that are beyond the capabilities of other pharmaceutical companies. Maxwell is a true pioneer in this space, leading the world in our efforts for developing new, shelf-stable therapeutics against the world’s most neglected, dangerous and deadly pathogens." – Joshua McClure, CEO This partnership marks another step in Maxwell’s mission to create health for the world, safely and affordably. 🔗 Read more: https://lnkd.in/dxm85QKR

📢 Maxwell Biosciences is thrilled to announce the addition of José Antonio Alas to our Board of Directors! With over 30 years in global pharmaceutical leadership, including successful international business growth, public-private partnerships, and product launches, Alas is a key addition to our team as we push forward with our mission to create health for the world, safely and affordably. Alas’s career includes a leadership role as President & GM for Eli Lilly and Company across South Asia, the Middle East, Turkey, and Africa, where he made significant strides in expanding patient access to life-saving medications. By adding Alas’s expertise, we’re accelerating the development of our Claromers®—synthetic molecules inspired by the innate immune system—to target viruses, bacteria, fungi, and biofilms, all while protecting healthy cells. We’re thrilled to have his strategic vision guiding us. 👉 Read the press release: https://bit.ly/42zRz5i

📢 ICYMI: Last week, we announced that Maxwell Biosciences was awarded nearly $3M from MTEC | Medical Technology Enterprise Consortium to develop breakthrough battlefield antiseptics. This marks our third military contract this year—another major step in protecting soldiers from life-threatening infections in the field. This investment doesn’t just benefit our nation’s warfighters—it also accelerates Maxwell Biosciences' R&D across the board. Each breakthrough in battlefield medicine informs the development of infection-fighting technologies that can impact civilian healthcare too. Watch and share our video to learn more about the life-saving impact it could have. Spread the word about innovation that makes a difference. https://lnkd.in/eaPZnxed #biotech #biodefense #maxwellbiosciences #innovation #infectioncontrol

Congratulations to Maxwell Biosciences on their most recent award from MTEC | Medical Technology Enterprise Consortium in collaboration with various other groups affiliated with the U.S. Department of Defense. This significant non-dilutive funding provides further validation that Maxwell's broad-spectrum, pathogen-agnostic anti-infectives are of serious interest to various military and defense organizations. Maxwell's novel #Claromer compounds have benefitted from years of third-party validation from independent labs run by universities and governments around the world and it's great to see this additional support from #MTEC. I look forward to hearing about the results as these studies strive to further validate Maxwell's technology as a way to safely and effectively prevent & treat infectious pathogens. #MaxwellBiosciences #Innovation #InfectionPrevention #MilitaryMedicine #Antimicrobial #Biotechnology

Thanks, Microdose Psychedelic Insights, for the feature. We appreciate the platform for more folks to hear from our visionary CEO, Joshua McClure.